Page last updated: 2024-12-08

furimidazoline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

furimidazoline: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID456460
CHEMBL ID58173
SCHEMBL ID549282
MeSH IDM0331537

Synonyms (10)

Synonym
2-[4-[5-[4-(4,5-dihydro-1h-imidazol-2-yl)phenyl]-2-furyl]phenyl]-4,5-dihydro-1h-imidazole
furan der.
2,5-bis[4-imidazolinphenyl]-furan
furimidazole
furimidazoline
CHEMBL58173
1h-imidazole, 2,2'-(2,5-furandiyldi-4,1-phenylene)bis[4,5-dihydro-
80498-71-1
SCHEMBL549282
DTXSID20332431
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID340909Binding affinity to Clostridium perfringens genomic DNA assessed as decrease in fluorescence intensity at 1 uM by fluorescence spectral method relative to control2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Diphenyl furans and aza analogs: effects of structural modification on in vitro activity, DNA binding, and accumulation and distribution in trypanosomes.
AID340904Binding affinity to poly(dA).poly(dT) assessed as increase in melting temperature2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Diphenyl furans and aza analogs: effects of structural modification on in vitro activity, DNA binding, and accumulation and distribution in trypanosomes.
AID340905Binding affinity at d(CGCGAATTCGCG) synthetic oligomer duplex assessed as increase in melting temperature2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Diphenyl furans and aza analogs: effects of structural modification on in vitro activity, DNA binding, and accumulation and distribution in trypanosomes.
AID38040Drug concentration required to inhibit B16 cell growth by 50% after 72 hours of incubation2002Journal of medicinal chemistry, May-09, Volume: 45, Issue:10
Distribution of furamidine analogues in tumor cells: influence of the number of positive charges.
AID478754Binding affinity to d(CGCGAATTCGCG)2 dodecamer assessed as change in melting temperature2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Theoretical models of pentamidine analogs activity based on their DNA minor groove complexes.
AID340902Antitrypanosomal activity against Trypanosoma brucei brucei S427 after 72 hrs2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Diphenyl furans and aza analogs: effects of structural modification on in vitro activity, DNA binding, and accumulation and distribution in trypanosomes.
AID340903Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 after 72 hrs2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Diphenyl furans and aza analogs: effects of structural modification on in vitro activity, DNA binding, and accumulation and distribution in trypanosomes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's4 (57.14)29.6817
2010's2 (28.57)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.82 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]